The clinical spectrum of IgM-related amyloidosis: A french nationwide retrospective study of 72 patients

Medicine

Volumn 87, Issue 2, 2008, Pages 99-109

  Terrier, Benjamin ^a,n   Jaccard, Arnaud ^b   Harousseau, Jean Luc ^c   Delarue, Richard ^a   Tournilhac, Olivier ^d   Hunault Berger, Mathilde ^e   Hamidou, Mohamed ^c   Dantal, Jacques ^c   Bernard, Marc ^f   Grosbois, Bernard ^f   Morel, Pierre ^g   Coiteux, Valérie ^h   Gisserot, Olivier ⁱ   Rodon, Philippe ^j   Hot, Arnaud ^k   Elie, Caroline ^a   Leblond, Véronique ^l   Fermand, Jean Paul ^m   Fakhouri, Fadi ^a,n  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g Service d'Hématologie   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ Military Teaching Hospital Sainte Anne   (France)

^j Responsable Consultation de la Douleur   (France)

^k HOSPICES CIVILS DE LYON   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTHRACYCLINE DERIVATIVE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN M; MELPHALAN; PURINE DERIVATIVE; RITUXIMAB; STEROID; THALIDOMIDE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMYLOIDOSIS; ARTICLE; CLINICAL DECISION MAKING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 40949118579     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b13e31816c43b6     Document Type: Article

References (36)

1. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101:3801-3808.
2. Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005;23:4662-4668.
3. Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, Chitale DA, Moscowitz C, Dhodapkar MV, Teruya-Feldstein J, Filippa D, Comenzo RL. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. Br J Haematol. 2004;124:309-314.
4. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98:714-720.
5. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol. 2003;30:220-225.
6. Dimopoulos MA, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, Gika D, Karmiris T, Bourantas K, Zomas A, Mitsouli C, Xilouri I, Vervessou E, Matsis K, Anagnostopoulos N, Economopoulos T. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol. 2003;14:1299-1305.
7. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909.
8. Fujii H, Yashige H, Kanoh T, Urata Y. [An unusual case of localized form of primary macroglobulinemia developing from a nodular primary pulmonary amyloidosis]. Rinsho Ketsueki. 1992;33:371-376.
9. Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, Rodriguez-Garcia JA, Masso P, Perez-Aliaga A, Monteagudo MD, Navarro I, Moreno G, Toledo C, Alonso A, Besses C, Besalduch J, Jarque I, Salama P, Rivas JA, Navarro B, Blade J, Miguel JF. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115:575-582.
10. Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, Cohen AM. Waldenstrom's macroglobulinemia associated with AA amyloidosis. Int J Hematol. 2001;74:76-78.
11. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319-328.
12. Gertz MA, Kyle RA. Amyloidosis with IgM monoclonal gammopathies. Semin Oncol. 2003;30:325-328.
13. Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol. 1993;11:914-920.
14. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006;133:158-164.
15. Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res. 2005;11:1786-1790.
16. Gobbi PG, Bettini R, Montecucco C, Cavanna L, Morandi S, Pieresca C, Merlini G, Bertoloni D, Grignani G, Pozzetti U, et al. Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939-2945.
17. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
18. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083-1093.
19. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ III. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
20. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF, Melton LJ III. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759-3764.
21. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786-1791.
22. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
23. Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B. Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med. 1990;172:1865-1867.
24. Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, Deliliers GL, Gobbi PG. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:211-215.
25. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, Facon T, Dervite I, Bauters F, Najman A, de Gramont A, Wattel E. Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852-858.
26. Moyner K, Sletten K, Husby G, Natvig JB. An unusually large (83 amino acid residues) amyloid fibril protein AA from a patient with Waldenstrom's macroglobulinaemia and amyloidosis. Scand J Immunol. 1980;11:549-554.
27. Ogami Y, Takasugi M, Soejima M, Kuroiwa A, Oma H, Nakano M, Haratake J, Toyoshima M, Watanabe T. Waldenstrom's macroglobulinemia associated with amyloidosis and crescentic glomerulonephritis. Nephron. 1989;51:95-98.
28. Okuda M, Okuda Y, Ogura T, Kashio M, Masuno T, Oji Y, Miyazaki M. Primary lung involvement with amyloid deposition in Waldenstom's macroglobulinemia: observations from over 20 years. Respirology. 2004;9:414-418.
29. Owen RG, Barrans SL, Richards SJ, O'Connor SJ, Child JA, Parapia LA, Morgan GJ, Jack AS. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116:420-428.
30. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110-115.
31. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81:693-703.
32. Sanchorawala V, Blanchard E, Seldin DC, O'Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol. 2006;81:692-695.
33. Valente M, Roy V, Lacy MQ, Dispenzieri A, Gertz MA. Autologous stem cell transplantation and IgM amyloidosis. Leuk Lymphoma. 2006;47:1006-1012.
34. Valleix S, Drunat S, Philit JB, Adoue D, Piette JC, Droz D, MacGregor B, Canet D, Delpech M, Grateau G. Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family. Kidney Int. 2002;61:907-912.
35. Wallace MR, Dwulet FE, Conneally PM, Benson MD. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest. 1986;78:6-12.
36. Yoshida T, Yazaki M, Gono T, Tazawa K, Morita H, Matsuda M, Funakoshi K, Yuki N, Ikeda S. Severe cranial nerve involvement in a patient with monoclonal anti-MAG/SGPG IgM antibody and localized hard palate amyloidosis. J Neurol Sci. 2006;244:167-171.